CA 27.29 antigen in serum of patients previously treated for stage II or stage III breast cancer. Serial testing for CA 27.29 antigen in patients who are clinically free of disease should be used in conjunction with other clinical methods for the early detection of recurrence. Carcinoma of the breast is the most prevalent form of cancer in women. These tumors often produce mucinous antigens that are large-molecular-weight glycoproteins with O-linked oligosaccharide chains. Monoclonal antibodies directed against these antigens have been developed, and several immunoassays are available to quantitate the levels of tumor-associated mucinous antigens in serum. The antibodies recognize epitopes of a breast cancer-associated antigen encoded by the human mucin 1 (MUC-1) gene, which is known by several names including MAM6, milk mucin antigen, CA 27.29, and cancer antigen CA 15-3. While CA 27.29 is expressed at the apical surface of normal epithelial cells, it is present throughout malignant epithelial cells of the breast, lung, ovary, pancreas, and other sites.
No special preparation is needed for CA 27.29. Inform your doctor if you are on any medications or have any underlying medical conditions or allergies before undergoing CA 27.29. Your doctor depending on your condition will give specific instructions.
|FEMALE||All age groups||0-38U/ml|